机译:脓毒症诱导患者诱导抗冲击适应性临床试验中脓液休克瘦素评价计划中成人自适应相2B / 3临床试验的理由和设计
Harbor UCLA Med Ctr Dept Emergency Med Bldg D9 1000 West Carson St Torrance CA 90509 USA;
Univ Pittsburgh Sch Med Clin Res Invest &
Syst Modeling Acute Illness Ctr Dept Crit Care Med;
Catholic Univ Louvain St Luc Univ Hosp Dept Crit Care Med Brussels Belgium;
Ferring Pharmaceut AS Copenhagen Denmark;
Ferring Pharmaceut AS Copenhagen Denmark;
Ferring Pharmaceut AS Copenhagen Denmark;
Berry Consultants LLC Austin TX USA;
Univ British Columbia St Pauls Hosp Ctr Heart Lung Innovat Vancouver BC Canada;
StraDevo AS Lyngby Denmark;
Ferring Pharmaceut AS Copenhagen Denmark;
Univ Pittsburgh Sch Med Dept Emergency Med Pittsburgh PA USA;
Brown Univ Alpert Med Sch Infect Dis Div Providence RI 02912 USA;
Ferring Pharmaceut AS Copenhagen Denmark;
CHU Limoges Ctr Invest Clin 1435 Limoges France;
Rigshosp Dept Intens Care Copenhagen Denmark;
Radboud Univ Nijmegen Med Ctr Dept Intens Care Med Nijmegen Netherlands;
Berry Consultants LLC Austin TX USA;
septic shock; adaptive clinical trial design; vasopressor treatment;
机译:脓毒症诱导患者诱导抗冲击适应性临床试验中脓液休克瘦素评价计划中成人自适应相2B / 3临床试验的理由和设计
机译:Selepressin VS安慰剂对脓毒症休克患者呼吸机和血管加压素的影响:败血症随机临床试验
机译:Selepressin是一种新型的选择性加压素V1A激动剂,在败血性休克患者的IIa期随机,安慰剂对照试验中可有效替代去甲肾上腺素
机译:评估在线临床试验对临床试验意识和应计费用的影响
机译:用于临床试验分析的自适应方法的比较:进入贝叶斯窗口,进入一些经常未被充分利用的临床试验分析方法。
机译:基于疗效和后续III期成功预测可能性的左旋肉碱评估适应性II期剂量寻找临床试验设计
机译:Selepressin是一种新型的选择性加压素V1A激动剂,在败血性休克患者的IIa期随机,安慰剂对照试验中可有效替代去甲肾上腺素